SG11202010463TA - Nlrp3 modulators - Google Patents

Nlrp3 modulators

Info

Publication number
SG11202010463TA
SG11202010463TA SG11202010463TA SG11202010463TA SG11202010463TA SG 11202010463T A SG11202010463T A SG 11202010463TA SG 11202010463T A SG11202010463T A SG 11202010463TA SG 11202010463T A SG11202010463T A SG 11202010463TA SG 11202010463T A SG11202010463T A SG 11202010463TA
Authority
SG
Singapore
Prior art keywords
nlrp3 modulators
nlrp3
modulators
Prior art date
Application number
SG11202010463TA
Other languages
English (en)
Inventor
Yong Zhang
Ashvinikumar V Gavai
Andrew F Donnell
Shomir Ghosh
William R Roush
Prasanna Sivaprakasam
Steven P Seitz
Jay A Markwalder
Original Assignee
Innate Tumor Immunity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66677224&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202010463T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Tumor Immunity Inc filed Critical Innate Tumor Immunity Inc
Publication of SG11202010463TA publication Critical patent/SG11202010463TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
SG11202010463TA 2018-04-25 2019-04-24 Nlrp3 modulators SG11202010463TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862662240P 2018-04-25 2018-04-25
US201862764818P 2018-08-16 2018-08-16
US201962825044P 2019-03-28 2019-03-28
PCT/US2019/028823 WO2019209896A1 (en) 2018-04-25 2019-04-24 Nlrp3 modulators

Publications (1)

Publication Number Publication Date
SG11202010463TA true SG11202010463TA (en) 2020-11-27

Family

ID=66677224

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010463TA SG11202010463TA (en) 2018-04-25 2019-04-24 Nlrp3 modulators

Country Status (17)

Country Link
US (1) US20210267964A1 (zh)
EP (2) EP3784670B1 (zh)
JP (2) JP7351850B2 (zh)
KR (1) KR20210005106A (zh)
CN (2) CN112074516A (zh)
AU (1) AU2019261582A1 (zh)
BR (1) BR112020021539A2 (zh)
CA (1) CA3097865A1 (zh)
CL (1) CL2020002719A1 (zh)
CO (2) CO2021006672A2 (zh)
IL (1) IL278173A (zh)
MX (1) MX2020011234A (zh)
PE (1) PE20210160A1 (zh)
SG (1) SG11202010463TA (zh)
TW (1) TW202014420A (zh)
WO (1) WO2019209896A1 (zh)
ZA (1) ZA202007307B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
IL297165A (en) * 2020-04-16 2022-12-01 Incyte Corp Soysag tricyclic CRS inhibitors
US20230183249A1 (en) 2020-04-30 2023-06-15 Janssen Pharmaceutica Nv New triazinoindole compounds
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
WO2022037631A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
EP3984535A1 (en) * 2020-10-16 2022-04-20 Albert-Ludwigs-Universität Freiburg Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
CN114539095A (zh) * 2020-11-26 2022-05-27 乐凯化学材料有限公司 3-（4-羟基-3-甲氧基-苯基）-2-氰基-2-丙烯酸乙酯的制备方法
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
ES2340745T3 (es) 1998-12-23 2010-06-08 Pfizer Inc. Anticuerpos monoclonales humanos contra ctla-4.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20070259907A1 (en) * 2004-06-18 2007-11-08 Prince Ryan B Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
KR101573109B1 (ko) 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
EP2992017B1 (en) 2013-05-02 2020-11-18 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
JP6563906B2 (ja) 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−１に結合する抗原結合蛋白質
CN104418867B (zh) * 2013-08-26 2016-12-28 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
CN105523955B (zh) * 2015-12-14 2018-08-17 北京嘉林药业股份有限公司 化合物及其在制备药物中的用途
CN111491362B (zh) 2016-02-02 2023-10-24 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2017252640A1 (en) * 2016-04-19 2018-12-06 Innate Tumor Immunity, Inc. NLRP3 modulators
US10533007B2 (en) * 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators

Also Published As

Publication number Publication date
TW202014420A (zh) 2020-04-16
CN112521387A (zh) 2021-03-19
AU2019261582A1 (en) 2020-11-12
CO2020013155A2 (es) 2021-06-10
PE20210160A1 (es) 2021-01-26
JP2024001030A (ja) 2024-01-09
ZA202007307B (en) 2023-01-25
CN112074516A (zh) 2020-12-11
US20210267964A1 (en) 2021-09-02
CL2020002719A1 (es) 2020-12-18
KR20210005106A (ko) 2021-01-13
CN112521387B (zh) 2023-08-22
EP3784670A1 (en) 2021-03-03
JP7351850B2 (ja) 2023-09-27
CO2021006672A2 (es) 2021-06-10
EP4353235A2 (en) 2024-04-17
MX2020011234A (es) 2020-11-11
IL278173A (en) 2020-11-30
EP3784670B1 (en) 2023-11-29
JP2021522249A (ja) 2021-08-30
WO2019209896A1 (en) 2019-10-31
BR112020021539A2 (pt) 2021-01-19
CA3097865A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
IL262303A (en) Modulators of nlrp3
ZA201906104B (en) Substituted imidazo-quinolines as nlrp3 modulators
ZA202007307B (en) Nlrp3 modulators
SI3743406T1 (sl) Modulatorji TMEM16A
IL271935A (en) NLRP3 modulators
GB2594008B (en) Modulators
GB201801614D0 (en) Formulation
GB201716468D0 (en) Modulators
IL289890A (en) nlrp3 modulators
GB201817859D0 (en) Aerosolisable formulation
EP3532062A4 (en) ROR-GAMMA MODULATORS
GB201817862D0 (en) Aerosolisable formulation
GB201816447D0 (en) Formulation
GB201817863D0 (en) Aerosolisable formulation
GB201803487D0 (en) Displays
EP3756513C0 (en) CARDBOARD DISPLAY
GB201809760D0 (en) Display
GB201807312D0 (en) Formulation
GB201803489D0 (en) Displays
GB2585587B (en) Modulators
GB2563095B (en) Modulators
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201809575D0 (en) Formulation
GB201702926D0 (en) Modulators